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INTRODUCTION AND HISTORICAL ASPECTS
Chagas disease is one of the most serious para-
sitic diseases of Latin America, with a social and
economic impact far outweighing the combined
effects of other parasitic diseases such as malaria,
leishmaniasis and schistosomiasis.  Serological data
indicate well over 16 million people are infected
with the causative agent, Trypanosoma cruzi, with
a further 100 million people considered at risk
(WHO 1991). The World Bank, in 1993, calcu-
lated an annual loss due to Chagas disease of
2,740,000 ‘disability-adjusted life years’ (DALYs),
representing an economic loss to the endemic coun-
tries of Latin America equivalent to over US$6.5
billion per year (WHO 1997, Schofield & Dias
1999).
Control of Chagas disease is now given high
priority by Latin American governments, partly
because of its high economic impact and conse-
quent financial benefits of effective control (eg.
Schofield & Dias 1991, Akhavan 1996, Basombrio
et al. 1998) but also because of the technical feasi-
bility of control through the interruption of trans-
mission.  In 1991 a major regional initiative to
eliminate Chagas disease was launched by the gov-
ernments of Southern Cone countries (Argentina,
Bolivia, Brazil, Chile, Paraguay, and Uruguay) (cf.
Kingman 1991, Schofield & Dias 1999), which has
recently been followed by similar initiatives in
Andean Pact countries (Colombia, Ecuador, Peru,
and Venezuela) and Central America (El Salvador,
Guatemala, Honduras, Nicaragua) (Schofield &
Dujardin 1997, WHO 1997).
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Chagas disease can be transmitted by several
mechanisms. Numerically however, vector-borne
transmission is the most important, generally ac-
counting for over 80% of all transmission of T. cruzi
to humans. Direct observations, and mathematical
models, indicate that social and political develop-
ment of the endemic regions could be sufficient to
control Chagas disease (and many associated prob-
lems).  Yet this route is complex in the less devel-
oped regions, largely because it involves rural ar-
eas that traditionally receive little political priority
(Caldas Jr 1980, Litvoc 1985, Dias 1987).  But the
epidemiological patterns of Chagas disease present
a series of vulnerable points that can be attacked
through national or regional control programmes.
Regrettably, neither vaccines to prevent infection,
nor drugs suitable for large-scale treatment, are cur-
rently available, but techniques for the interrup-
tion of transmission are now well established and
are being progressively implemented throughout
the endemic areas of Latin America.
Today, there is a general consensus that human
Chagas disease will be overcome through inter-
ventions against different levels in the cycle of
transmission  (WHO 1991, Dias 1993a, b,
Schofield 1994).  At the primary level, interven-
tions are designed to prevent transmission.  At the
secondary level, interventions are designed to pre-
vent or inhibit disease in cases where infection has
occurred, while at the tertiary level the interven-
tions seek to limit human incapacity and reinte-
grate infected people into the community (Dias
1997). This paper presents a summarised overview
of the control of Chagas disease, considering some
historical aspects and the general context of the
fight against the disease in endemic countries.
The discovery of Chagas disease constitutes one
of the most exciting pages of the history of medi-
cal science. In parallel with the clinical, epidemio-
logical, biological and pathological aspects that he
studied,  Carlos Chagas stated very early that, first
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of all, control of the disease represented a “duty
for the State”. In his admirable work, Chagas
pointed out that control of transmission would be
the most desirable goal and the best strategy in the
fight against the disease which now bears his name.
His comprehension about the problem was estab-
lished in three basic points (Chagas 1911): (1) the
epidemiological and social impact of the disease
would be extremely relevant, considering the very
large dispersion of the vector and the possibilities
of high prevalence of human infection in Brazil
and other countries of Latin America; (2) the basic
focus on governmental programmes against the
disease would be of preventive nature, since the
cure of human T. cruzi infection had many techni-
cal problems and the control of transmission cer-
tainly would be the most vulnerable point to inter-
vention in the epidemiological chain, and; (3) the
fundamental point for intervention would involve
vector control. Nevertheless, Chagas suspected that
other mechanisms of transmission existed, for in-
stance, congenital transmission.
Carlos Chagas very soon realised that political
aspects might primarily be involved  in disease
control, since he perceived that  human American
trypanosomiasis (HAT) was basically a disease af-
fecting extremely poor rural populations who were
living in very bad housing conditions, such a situ-
ation providing an ideal condition to vector
colonisation. Chagas stated that the main frame for
the HAT undoubtedly  would the house infested
by triatomine bugs and clearly said in his famous
II Conference (Chagas 1911):
“Cumpre salientar que o principal facto
epidemiologico da moléstia é constituido por um
insecto, companheiro constante do homem nos
domicilios e, por isso mesmo, facilmente attingivel
às medidas de destruição....Medidas sanitarias
nesse sentido, visando, sobretudo, modificar as
condições de habitabilidade .....importariam, sem
dúvida, em acto administrativo do maior proveito”.
(“It is clear that the basic epidemiological fact
of the disease is constituted by an insect, a con-
stant companion of men in their houses, and thus
easily vulnerable to destruction....Sanitary mea-
sures in this sense, especially improvement  of the
living conditions, would certainly represent an
administrative act of major importance”).
Chagas was an excellent malariologist, prob-
ably the most important in Brazil at that time. He
was in charge of an anti-malaria campaign in Minas
Gerais when he discovered the trypanosomiasis.
Nevertheless, since his first works he stated very
clearly what were the  main differences in clinical
and pathological aspects of these diseases, and also
discussed possible strategies of control. Vaccina-
tion was not feasible for either disease, and spe-
cific treatment would certainly present difficulties
in trypanosomiasis. Because  effective insecticides
against triatomine bugs did not exist at that time
(in contrast with malaria, for which mosquito lar-
vicides were available and used by Chagas), his
attention was directed to housing improvement.
One of Chagas’ disciples, HC Souza Araujo (1919),
had an important influence, proposing in the state
of Paraná  (Brazil) a law making compulsory  house
improvement in endemic areas to prevent HAT.
However, this law was never implemented during
Chagas’ life, and there were no government or re-
gional efforts to break the disease transmission until
the end of the 1940s (Chagas died in 1934).  But
Chagas was conscious of the difficulties of HAT
control, in spite of his tremendous anxiety to face
the disease in all possible ways. Very soon he per-
ceived that political will never would come unless
the disease and its social and economical impact
were recognised. An entomological line of research
at laboratory and field level was swiftly developed
in “Manguinhos” and in several parts of the Ameri-
cas, providing important information about vector
and parasite distribution throughout the continent.
But this line would  not be sufficient, since the basic
political subject was not the parasite, but human
disease. At this point, Chagas worked in several
projects seeking to clarify the epidemiology of
HAT, particularly in relation to diagnosis and clini-
cal characterisation of the chronic phase of the dis-
ease – especially chronic heart disease (Laranja
1949, Dias 1988). Nevertheless, during the first
30 years after the discovery, knowledge of the dis-
ease remained polarised  between entomological
aspects and the acute phase of  HAT – reflecting
the fashion for microbiological research of that
time. Another constraint was the lack of interest of
European and North American researchers to study
a strictly Latin American pathology. At that time,
Latin American countries were independent and
their attractive mines of gold, silver and other pre-
cious minerals were rapidly becoming non-produc-
tive. European attention was focused on their colo-
nies in Asia and Africa, where classical institutes
for tropical medicine were installed. Carlos Chagas
and Oswaldo Cruz were conscious of these facts,
but still sought to interest the international scien-
tific community in the new pathology discovered
in Lassance. Chagas’ works were therefore pub-
lished in the USA, Europe and Argentina,  written
in English, French, German and Spanish. Impor-
tant figures such as Hartmann, Prowazek,
Metchnikoff, Brumpt, Crowell and Laveran were
contacted, but Chagas reserved his greatest efforts
to prepare his own group at the national level.   In
1913 Chagas induced his assistants C Guerreiro
and A  Machado to apply the Bordet and Gengou
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technique to detect anti-T.cruzi antibodies in
chronic patients. At the same time he began to de-
velop his own research on chronic disease, latterly
with the assistance of Eurico Villela and Evandro
Chagas who chiefly focused on chronic cardiopa-
thy. For them, it soon became clear that chronic
heart disease  was the most relevant aspect of all
HAT (Dias 1988,  Coura 1997). Once more Chagas
was proved correct, but again he could not escape
from another personal frustration: in spite of his
magnificent descriptions, the clinical and patho-
logic aspects of chronic disease were not appreci-
ated by the majority of scientists of his time. In
parallel, serological diagnosis of chronic infection
only became generalised in the 1940s following
successful work carried out in Bambuí (E Dias &
cols) and in São Paulo (P Freitas & cols); in the
same way, chronic chagasic cardiopathy only be-
came widely  at the end of the 1940s, again fol-
lowing detailed studies by the Bambuí group
(Laranja et al. 1956,  Dias 1988, Coura 1997). Data
collected by Laranja (1949) about the evolution of
knowledge and the description of the chronic
chagasic  cardiopathy (CCC) can be summarised
as follows: (a) until 1930, cases of CCC were only
described in Lassance, by Chagas and Villela; (b)
from 1930 to 1944, only 45 new CCC cases were
described in Brazil, all from Lassance; (c) the first
case of CCC described outside Brazil was pub-
lished in Argentina, 1934, where 133 other cases
were detected up to 1944; ( d) in Brazil, between
1944 and 1948, another 600 cases of CCC were
registered, mainly from Bambuí; (e) in contrast,
from 1909 to 1948, more than 2.000 acute cases
were registered, the majority of them in Argentina,
Brazil and Uruguay.
Chagas remained patient. In his last  works and
conferences, he still  emphasised  the chronic as-
pects of the disease, certainly waiting for confir-
mation of his findings elsewhere. In 1932 (pub-
lished in 1934) he wrote:
 “Firstly verified in Brazil, in the hinterland of
Minas Gerais, this other human trypanosomiasis
is not an exclusive disease of our country, since it
was also recognised in other countries of South
and Central America. In Argentine, in Tucuman
and Catamarca provinces, several clinical cases
were observed, with the verification of the para-
site in their peripheral blood, as well as in Peru,
Venezuela, San Salvador and, recently, in Panamá.
But we  still have little knowledge concerning the
endemic index and the social importance of the
disease in these other American countries...”
(Chagas 1934).
At the same time, in spite of the sad episode of
the National Academy of Medicine (where medio-
cre and jealous enemies aggressively questioned
Chagas) he never lost his hope in the force of sci-
ence to control diseases and to improve health  for
the people:
 “The European nations, zealous of their colo-
nies in the tropics, have organised  the expertise -
in their universities and in their great research in-
stitutes - to the study and the teaching of  pathol-
ogy in tropical countries. Here, not so much the
economic interests, but the most exalted duties and
provident nationalism oblige us to study and to
research the Brazilian nosology, in order to pro-
vide the improvement of our race, of rare native
attributes, and to reach, by the prophylactic method,
the sanitary redemption of our large territory”
(Chagas 1926).
THE MODERN ERA OF CHAGAS DISEASE CON-
TROL
Vector control
In the 1930s, an increasing number of acute
cases were being detected in Argentina  by Mazza,
Romaña, etc., and in Uruguay (by Talice & Rial)
following important work by MEPRA in Argen-
tina – particularly the description of Romaña’s sign
as a diagnostic indication of acute infection. There
were attempts at prevention, chiefly by Talice and
Mazza, focusing again the question of housing
improvement. But systematic control efforts only
began to develop when a small branch of the
Oswaldo Cruz Institute was set in Bambuí, Minas
Gerais, where dozens of acute cases were detected
by Vianna Martins (a general parasitologist) and
subsequently by Emmanuel Dias (one of Chagas’
disciples), in the beginning of the 1940’s. This
“Centro de Estudos e Profilaxia da Moléstia de
Chagas do Instituto Oswaldo Cruz “ represents the
first institutional effort to promote Chagas disease
control. It was promoted through the influence of
Evandro Chagas and Amilcar Vianna Martins and
implemented by Emmanuel Dias, under the deci-
sion of the Institute Director, Dr Henrique Aragão.
In 1943/44, Dias made a complete survey of the
municipality, finding astonishing epidemiological
indicators such as a house infestation rate of 70%,
natural infection of the bugs by T.cruzi around 30-
40%, and 45% of positive serology among rural
children under 10 years old (Dias 1944, 1997). Two
basic research lines were established between 1943
and 1961: (a) control of transmission, focused
mainly on vector control, and, (b) the study and
clinical characterisation of chronic heart disease.
The first line was immediately started by means of
physical and chemical control of domestic vectors,
including house improvement and intensive health
education. The second line demanded development
of a complex  research structure, involving cardi-
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ologists (mainly Dr Francisco Laranja), general
doctors (Dr Genard Nóbrega), serologists (particu-
larly Dr Julio Muniz) and pathologists (Drs
Magarinos Torres and A Miranda), all leaded  by
Emmanuel Dias. The first clinical studies were
performed between 1945 and 1956, resulting in
several publications about acute and chronic
Chagas disease, focused particularly on cardiac
pathology. The group also looked for experimen-
tal models, succeeding in reproducing all aspects
of the human disease in dogs and monkeys (Laranja
1949, Dias 1993-c). In 1956 the group published
their conclusions about Chagas cardiopathy in Cir-
culation (the most important medical journal on
cardiology, at that time), a work which is still con-
sidered as the definitive contribution about the
characteristics of chronic Chagas heart disease
(Laranja et al. 1956). In relation to disease preven-
tion, Dias easily reached the conclusion that the
transmission of T. cruzi to man was directly de-
pendent on  infected vector populations in human
dwellings, realising the  correlation between inci-
dence and prevalence of human disease and the
level of infested houses (Dias 1944, Hayes &
Schofield 1990). In his early attempts, Dias tried
everything he could imagine to kill or remove
triatomines from human dwellings. His  early ap-
proaches included throwing boiling water, caustic
soda, or kerosene, over the walls of infested houses,
and even limited attempts using military flame
throwers. At that time, the best results were ob-
tained employing a mixture of rotenone and kero-
sene (C23 H22 O6), by which an  enormous knock
down effect was obtained against domestic Tri-
atoma infestans and Panstrongylus megistus infes-
tation. This gave an immediate reduction in the
number of acute cases, especially when houses
were also submitted to physical improvement (Dias
1944).      Several other approaches have been tried
but with the development of synthetic insecticides
in the 1940s, chemical methods of vector control
have become the most widely used technique,
backed by low-cost systems of house improvement
and community health education.  DDT was found
ineffective against most species of Triatominae
(although it does have a latent effect against some
species) but good results were obtained in early
trials with another organochlorine, gamma-BHC
(also known as HCH, Lindane or Gammexane)
(Dias & Pellegrino 1948, Romaña & Abalos 1948).
BHC (and/or dieldrin) remained the most widely
used compound against domestic Triatominae un-
til the late 1970s when it was progressively replaced
with synthetic pyrethroids (Schofield 1994, Dias
1997).
By the end of the 1940s all the main tools and
strategies for the control of domestic Triatominae
were available, at least at the experimental or theo-
retical level. E Dias recruited to his group a bril-
liant medicine student, José Pellegrino, who helped
him very much in the work. Other  research groups
were also developing work on the control of
Triatominae, chiefly in Brazil [Freitas (1963) in S.
Paulo,  Szumlewiecs (1953), in Rio] and in Ar-
gentina (Romaña & Abalos 1948). Nevertheless,
large-scale control programmes could not start until
the beginning of the 1960s, because of the lack of
political decision and the absence of national struc-
tures capable of implementing control programmes.
For these reasons, Emmanuel Dias put his best ef-
forts to stimulate the national director of the Bra-
zilian Endemic Diseases Programme (DNERu), Dr
Mário Pinotti, to launch a regional control trial in
Uberaba in the State of Minas Gerais during 1951-
1952. The results were excellent, and stimulated
other regional initiatives during the 1960s such as
the São Paulo State Programme (by Freitas, Rocha
e Silva & others) and large scale trials carried out
in Argentine (by Cichero, Soler and Abalos), in
Chile (by Neghme & Schenone) and in Venezuela
(by Pifano & Gabaldón) (Dias 1993-b, 1988). Na-
tional programmes followed, all based on chemi-
cal control methods against domestic Triatominae
and using the rationale and strategies of the suc-
cessful malaria campaigns. In Venezuela, as well
as insecticide application, a national programme
to improve rural dwellings was implemented, capi-
talising on the strong economy and public health
expertise of the country at that time (Dias 1988).
Through the 60s and 70s, a series of different con-
trol approaches were tested (Table 1) but insecti-
cides remained the most effective and efficient
approach (Dias 1957, 1994, 1997, Rabinovich et
al. 1979, Rocha e Silva 1979, WHO 1991).
The introduction of synthetic pyrethroids in the
early 80s was a major advance in campaigns to
control domestic Triatominae.  All those currently
used are alpha-cyano-substituted pyrethroids, ap-
plied as wettable powder (WP) or suspension con-
centrate (flowable) (SC) formulations using con-
stant pressure backpack sprayers,  generally of 8
or 10 l capacity.  These pyrethroids are fast acting
against the target Triatominae, and also provide
transient control of other domestic insect pests such
as fleas, cockroaches and houseflies.  They are
considerably more expensive per kg than the pre-
viously used organochlorine insecticides, but are
applied at much lower doses (Table II).  Compara-
tive studies show them to be considerably more
cost effective (eg. Oliveira Filho 1989, Schofield
1994) and they have the additional advantages of
greater acceptability to householders (being
odourless and leaving no stains on the walls after
application) and safety (2500 times less toxic to
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mammals than organochlorines).  They are also
well accepted by spraymen, although they occa-
sionally produce transient irritation of the eyes and
mucosa during application. Other formulations of
conventional insecticides have been tried against
triatomines, chiefly looking for a more consistent
residual effect. These include microencapsulated
formulations of pyrethroids, and slow release PVC
matrices containing organochlorine or organophos-
phate (malathion) compounds. These formulations
tend to have more residual activity, but their final
cost-effectiveness  is usually no better than con-
ventional pyrethroids. Other approaches using
ionised micro drops of active ingredient (Electro-
dyne) and/or spatial ultra-low volume spraying
showed no advantages when compared with clas-
sical spraying methods. Synergists such as PBO
(Piperonyl butoxide) seem not improve the action
of pyrethroids against Triatominae (Dias 1997).
Among all triatomine species, undoubtedly the
most important has been T. infestans, responsible
for the majority of cases of Chagas disease in the
Continent. It is present in the six countries of South-
ern Cone, and in southern Peru, and is almost en-
tirely domestic throughout its wide distribution.
The spread of T. infestans to its current wide dis-
tribution  appears to have been relatively recent,
associated mainly with human migration patterns
(Schofield 1988). Since Emmanuel Dias and Alina
Szumlewics, in the 40s and 50s, the behavioural
biology and population dynamics of this species
have been intensively studied, and several com-
prehensive reviews have been published. First of
all, the species became almost completely domi-
ciliated in all its area of dispersion, with the ex-
ception of some restricted rural areas of Bolivia
TABLE I
Methods of control tested against domestic Triatominae
Conventional insecticides Organochlorine compounds (eg. BHC & Dieldrin), organophos-
phates (eg, malathion, fenitrothion), carbamates (eg. propoxur)
and modern pyrethroids (see Table II); advantages: cheap, effec-
tive, available, safe for mammals; disadvantages: loss of residual
activity on porous mud walls and peridomestic habitats
Insect growth regulators Eg: juvenile hormone mimics, precocenes; advantages: highly
specific; safe for mammals; disadvantages: slow acting, active
against only a few stages
Insect pathogens (eg. nematodes, fungi) Advantages: safe for mammals; disadvantages: greatly limited
by climatic factors, difficult application
Other biological control (eg. egg parasitoids) Advantages: safe for mammals; disadvantages: expensive,
ineffective.
Genetic control (eg. liberation of sterile Advantages: none; disadvantages: expensive, unethical to releas
or substerile males) e potential vectors
Traps (eg. baited with lights, kairomones) Advantages: none; disadvantages: ineffective
Housing improvement (eg. wall plaster, Advantages: effective; general improvement of living standards;
replacement of thatch roofs) disadvantages: difficult to implement on a large scale; tends to
be costly
Health education (eg. improve public Advantages: general improvement of education and living stan-
awareness, support of vigilance programmes) dards; disadvantages: great expectations are not always fulfilled
TABLE II
Types of pyrethroid insecticide and recommended dose of active ingredient to be applied for the elimination of
domestic Triatominae
Formulation Dose rate (mg a.i./sq, m) Manufacturer
Deltamethrin 2.5% SC (or 5% WP) 25 AgrEvo
Cyfluthrin 10% WP 50 Bayer
Beta-cyfluthrin 12.5% WP or SC 25 Bayer
Cypermethrin 20-40% WP 125 Various
Lambda-cyhalothrin 10% WP 30 Zeneca
SC: suspension concentrate (flowable); WP: wettable powder.
108 The Evolution of Chagas Disease  JCP Dias, CJ Schofield
where it can be found in sylvatic ecotopes
(Schofield 1994, Dias & Coura 1997). Of particu-
lar interest in relation to vector control  interven-
tions is the insect’s relatively slow rate of popula-
tion regeneration and the susceptibility of nymphs
and adult bugs to modern insecticides. In addition,
the bugs have a very specialised  genetic system
with holocentric chromosomes and extremely low
rates of genetic variability. The practical conse-
quences of these facts in vector control correspond
to the extreme difficulty these insects have in se-
lecting insecticide resistance. In summary, T.
infestans has at least four biological characteris-
tics functioning as key factors favouring its con-
trol: (a) limited range of habitats, with all stages
confined to houses and some  peridomestic animal
enclosures; (b) slow rate of population develop-
ment, and consequent low rate of genetic rearrange-
ment; (c) extreme specialisation with a low rate of
genetic variability and consequently limited genetic
repertoire for further adaptation (including insec-
ticide resistance), and, (d) complete susceptibility
to modern pyrethroid insecticides (Schofield &
Dias 1998).
Organisation of control campaigns against
Triatominae is generally based on the administra-
tive structures previously set up for campaigns
against other insect pests - particularly mosquito
vectors of yellow fever and malaria.  And the op-
erational procedure is also similar, with three main
phases of intervention: preparatory, attack, and
vigilance.  The preparatory phase mainly involves
arrangement of material and financial resources,
recruitment and training of personnel, and sketch-
mapping of the area to be treated - including, where
possible, baseline serological studies of the popu-
lation to determine initial infection rates.  The at-
tack phase generally involves large-scale spraying
of all premises in the target area, regardless of
whether or not an individual house is known to be
infested.  This is because available sampling meth-
ods are imprecise, and may not detect low-density
triatomine populations (Schofield 1978, Gurtler et
al. 1993). Householders are advised to remove all
foodstuffs and animals, and asked to pull furniture
away from the walls. All internal and external wall
surfaces are sprayed, together with the inside roof
surface and all peridomestic animal enclosures.
Following the attack phase, dwellings must be
evaluated for the presence of Triatominae by teams
of trained personnel using torch and forceps to
examine cracks and crevices in the house.  Some-
times sheets of paper (Garcia Zapata et al. 1985)
or special cardboard boxes (Gómez-Nuñez 1965)
are placed on the walls as passive sampling de-
vices; subsequent deposits of bug faeces on the
papers will indicate the presence of triatomine bugs.
If the post-spray evaluation indicates more than
5% of the houses still appear to be infested with
Triatominae, then the area is programmed for a
repeat application as in the original attack phase.
If less than 5% of houses appear to be infested,
then the area is placed under vigilance, whereby
any premises still infested can be selectively re-
treated.  The decision level at 5% house infesta-
tion rate has been determined on the basis of expe-
rience indicating that below this level new cases
of T.cruzi infection are rare (Dias 1987).
The vigilance phase depends crucially on the
participation of the local community, and is pre-
pared from the start of the campaign through com-
munity health education and discussion with local
community officials.  The idea is that all house-
holders are made aware of the objectives and ra-
tionale of the campaign, and can appreciate their
important role in its success.  In this way they can
assist the spraymen during the attack phase, and
then act as the ‘eyes’ of the control services during
the subsequent vigilance, reporting the presence
of triatomine bugs to the local information post, so
that the house can be rechecked and resprayed if
necessary.
Following this general schedule, the results
have been very satisfactory in Brazil, Uruguay,
Chile, and in large regions of Argentina, Venezu-
ela, and parts of Bolivia and Paraguay.  Where
vector control has been satisfactorily implemented
in these countries, acute cases of Chagas disease
are no longer seen, and serology of young chil-
dren (born since the launch of the control cam-
paigns) shows very low rates of infection (Dias
1993a, Schmunis et al. 1996, WHO 1997).  In ad-
dition, the prevalence of  T. cruzi infection is also
decreasing amongst blood donors and women of
child-bearing age, bringing corresponding reduc-
tions in the risk of transfusional and congenital
transmission (Dias 1997). Table III, from the offi-
cial reports of Southern Cone Initiative, shows the
reduction  of seropositivity over the last few years
(WHO 1997, Schofield & Dias 1999).
Consolidation of successful vector control in-
terventions depends on two important concepts,
applicable to different epidemiological situations.
The objective is to ensure that treated premises
remain free of triatomine bug infestations.  Con-
tinual retreatment with insecticides, as has been
carried out in the past against endophilic mosqui-
toes, is neither practical nor desirable, especially
given the slow rate of recolonisation of houses by
most triatomine species.  Instead, the strategy is to
inhibit reinfestations by: (a) eliminating all residual
foci of infestation that could give rise to new bug
colonies, and (b) progressive socio-economic de-
velopment and house improvement to render
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houses less amenable to bug infestations,  although
for both scenarios the importance of community-
based vigilance cannot be stressed too highly.  In
the case of highly domestic species of Triatominae,
such as T. infestans in Southern Cone countries,
new infestations arise primarily through passive
transport of bugs in the clothes and belongings of
people travelling from infested to non-infested
dwellings (Schofield 1988, Schofield & Dias
1998).  Consequently, the broad international strat-
egy (PAHO 1993, Schmunis et al. 1996) is to elimi-
nate all domestic foci of  T. infestans throughout
the region in order to eliminate the possibility of
passive transport of bugs from one region to an-
other.  In the case of species that retain silvatic
ecotopes however, complete elimination is impos-
sible, so that greater emphasis is placed on adequate
surveillance, selective retreatment of new infesta-
tions, and progressive improvement of rural hous-
ing (Schofield et al. 1990, Briceño-León 1993).
The new scenery of Chagas disease control
programmes is replacing the classical vertical by
the horizontal approach, since most of the coun-
tries  are turning their Public Health systems to the
decentralised model. In the years 90, globalisation
and market controlled economies imposed the gen-
eral tendency to deliver resources and responsi-
bilities to peripheral levels, in order to improve
small and efficient central and national structures.
In matter of fact, considering the general condi-
tions of the regions where Chagas disease exists,
the transition to decentralisation can be considered
another new challenge, since the very poor mu-
nicipalities and counties generally do not have
sufficient expertise, organisation and political will
to carry on the programme. Technically, at the
present time no major problems exist concerning
the fight against triatomines indoors: all the results
can be considered very optimistic in those areas or
regions where the programmes are being conducted
with a minimum of quality, coverage and continu-
ity (WHO 1991, Schofield  & Dias 1998). Never-
theless four other challenges emerge for the  new
century: (a) to maintain political decision (and natu-
rally the necessary resources) in those regions
where the disease impact fallen down;  (b) to face
objectively the irreversible tendency to centraliza-
tion. In other words, to maintain minimum central
and regional reference structures in order to im-
prove the efficacy and continuity of finalistic ac-
tivities at the peripheral level; (c) to control sec-
ondary and ubiquitous species at the peri-domes-
tic level, and,  (d) to maintain a high and perma-
nent degree of community participation in order to
improve a continuous epidemiological surveillance
(Dias 1987, 1991, Schofield & Dias 1999).
Control of transfusional transmission
Blood transfusion transmitting T. cruzi  was one
of the few subjects not suspected by Carlos Chagas,
but discovered at the end of the 40’s, after the ad-
vertising of Salvador Mazza, Emmanuel Dias and
other pioneers. Transfusion is considered the sec-
ond most important mechanism of transmission of
Chagas disease to which currently accounts for
around 15% of all transmission.  The required
methods for control of transfusional transmission
have been available since the 1950s, but have only
been adopted on a large scale since the emergence
of the Aids pandemic in the 1980s.  As HIV can
also be transmitted by blood transfusion – along
with other pathogens such as hepatitis and syphi-
lis – there is now greater emphasis on improving
the quality of blood for transfusion to eliminate
the risk of these infections.
There are three basic strategies according to the
epidemiological situation (Wendel et al. 1992). In
regions with high seroprevalence of T. cruzi infec-
tion amongst blood donors (20% or more) or where
serological screening systems are unavailable or
unreliable, the best approach is to add gentian vio-
let to stored blood (1:4000) for 24 hr in order to
kill any flagellates. This method has been very
widely used for many years, and the blue
colouration imparted to the transfused blood gen-
erally disappears a few days after transfusion.  In
areas with lower seroprevalence of  T. cruzi infec-
tion the recommended approach is to screen all
potential blood donors using at least two serologi-
TABLE III
Seroprevalence (in %) of Trypanosoma cruzi infection in five Southern Cone countries from large scale surveys
before and after initiation of the Southern Cone Programme (Schofield & Dias 1999)a
Country 1981 - 1985 1993 - 1995 Observations
Argentina 4.8 1.2 18 year-old military recruits
Brazil 4,5 (a) 0.2 (b) (a): general population; (b): 7-14 years old
Chile 5.4 1.4 < 10 years old
Paraguay 9.2 4.0 18 year-old military recruits
Uruguay 2.4 0.2 < 12 years old
a: values are percentage seropositive in the age groups shown.
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cal tests (usually Indirect Haemaglutination and
Indirect Fluorescent Antibody tests); at the same
time the blood can also be screened for HIV, hepa-
titis and syphilis (Dias 1978, Schmunis 1991, WHO
1991).  The third approach, used in non-endemic
areas such as the USA, is based on a preliminary
questionnaire to see if the donor has any history of
possible contact with T. cruzi or infected
Triatominae (eg. has previously lived in an endemic
region), which may then be followed by appropri-
ate serological testing.
For endemic Latin American countries, the
screening methods need to be complemented by
adequate legislation obliging a standardised sys-
tem of screening in all blood banks, and entirely
prohibiting the use of paid blood donors.  There is
a corresponding need to promote correct clinical
indications for the use of transfused blood and
haemoderivates, the correct and immediate notifi-
cation of transfusion accidents, and to stimulate
modern practices such as auto-haemotransfusion
(Wendel et al. 1992, Dias 1997).  The research need
is to improve serological screening techniques to
achieve greater sensitivity and specificity at re-
duced cost, and to develop a serological ‘gold stan-
dard’ for all reference laboratories.  Improved
chemoprophylaxis for stored blood would also be
helpful, because of the potential toxicity of Gen-
tian Violet and its slow rate of action (Moraes de
Souza et al. 1997).
Additionally, it is worth emphasising the inte-
grated approach to Chagas disease control, in the
sense that throughout the Americas blood banks
are now one of the most important sources of epi-
demiological information on the seroprevalence of
infection.  Data from blood banks provide a useful
baseline against which to judge the progress of
Chagas disease control programmes, offering an
important index of the changes in seroprevalence
as control programmes proceed.   Serological
screening prior to blood donation also offers an
important opportunity to identify infected individu-
als, who must be advised never to offer blood again
and must be referred for clinical follow up, coun-
selling, and supportive treatment where required
(Dias 1997,  Moraes de Souza et al. 1997, Dias &
Schofield 1998).
Control of congenital transmission
Congenital transmission of  T. cruzi, although
numerically small, is the third most important
mechanism of transmission.  Up to 4% of births
from infected mothers can result in infected ba-
bies due to parasites crossing the placenta
(Schmunis 1991, Dias & Coura 1997) suggesting
that up to 5000 new infections per year may be
due to this route of transmission.
Unfortunately, congenital transmission cannot
be prevented during pregnancy because available
drugs are toxic and teratogenic, and preventive
abortion is unacceptable.   There is also no reliable
way to detect intrauterine infections, so that the
best procedure consists of early diagnosis of the
new-born followed by specific treatment with
benznidazole (8-10 mg/kg/day during 60 days).
Serology can be carried out on pregnant women
with appropriate epidemiological history (eg. com-
ing from an endemic area), thus detecting those at
risk.  However, conventional serology is not diag-
nostic for new-bornes because the baby will re-
main seropositive for 4-5 months due to passive
transference of IgG antibodies from the infected
mother.  Instead, parasites can be sought directly
or by haemoculture or indirect xenodiagnosis from
the new-bornes, especially in those who present
continuous fever or other suggestive symptoms
such as myocarditis or hepato and splenomegaly.
In countries such as Brazil where congenital cases
are becoming rarer, the usual strategy is to use con-
ventional serology when the babies reach 6 months
(when maternal antibodies will have disappeared)
and immediately treat those who result positive
(Dias 1987, WHO 1991).
Control of transmission by organ transplant
Theoretically, transmission of   T. cruzi can oc-
cur by the transplant of virtually any organ from
infected donor to susceptible recipient.  However,
most cases have been recorded as a result of kid-
ney transplantation, with rare cases attributed to
transplants of heart, pancreas, and bone marrow.
Pre-surgery serology of both donor and recipient
should be obligatory in endemic areas, or when
either has an epidemiological history of possible
contact with the parasite.  Nevertheless, in urgent
cases the transplant must proceed and the best strat-
egy is specific treatment of the infected donor
(benznidazole 5-7 mg/kg/day) during the 10 days
preceding surgery, and similar treatment of the re-
cipient on the day before surgery and for 9 days
afterwards.  The rationale is to minimise circulat-
ing parasites in the donor in order to inhibit their
establishment n the recipient (Dias et al. 1986).  In
cases where pre-surgical treatment of an infected
donor is not possible, the recipient should be treated
immediately after surgery.  This applies also to
cases of transplant from an uninfected donor to an
infected recipient, since reactivation of acute
Chagas disease can result from the use of immu-
nosuppressants during transplant surgery (Ferreira
et al. 1997).
Accidental transmission
Accidental transmission of T. cruzi is regretta-
bly frequent in laboratories, and well over 50 cases
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have been recorded,  generally as a result of acci-
dental puncture from infected needles or splash-
ing with contaminated triatomine faeces or culture
material (Brener 1987).  This problem must be
addressed by very clear training of personnel and
rigorous attention to good laboratory procedures.
Laboratories should have a restricted entrance, and
the use of gloves, protective eye-glasses, masks,
closed shoes and long-sleeved gowns, should be
obligatory for technicians working with the para-
site.  Periodic serological checks of laboratory staff
are also advisable.  Immediate local sterilisation
must be provided after accidental contact with sus-
pect material, and silver nitrate eye washes are in-
dicated if the eyes were contaminated.  If a person
seems likely to have been infected, then an imme-
diate presumptive course of treatment should be
given, using benznidazole (5-7 mg/kg/day) for at
least 10 days.
Vaccination and chemoprophylaxis
Several forms of immunisation have been tested
against T. cruzi, using attenuated strains, fraction-
ated parasites, antigenically similar trypa-
nosomatids, and synthetic molecules.  None has
been effective. ‘Live’ vaccines could not assure
safety, while ‘killed’ vaccines could not provide
total protection, and further research aimed at pro-
ducing a vaccine against T. cruzi is no longer en-
couraged (WHO 1991).  Similarly there is no drug
that can be used for effective prophylaxis, for ex-
ample to protect travellers who visit endemic ar-
eas.  In this context however, it is worth
emphasising that the risk of infection to travellers
is extremely low.
Reactivation of human Chagas disease
As mentioned for organ transplanted individu-
als, some other situations involving immunologi-
cal depression can re-activate T. cruzi infection.
The most common situation concerns to HIV su-
perinfection in chagasic patients, chiefly when the
level of CD4 cells is lower than 300, generally re-
sulting in severe neurological pictures. More than
40 cases are known, most of them with fatal evo-
lution. Adequate treatment with anti retroviral
drugs are able to prevent reactivation in these cases.
Recently, it was also suggested to treat them with
benznidazole (5 mg/k/day three times weekly) in
order to maintain a small number of circulating
parasites (Ferreira et al. 1997).
Treatment of  infection
Although the primary emphasis in Chagas dis-
ease control concerns the interruption of transmis-
sion, there remains a need to treat people who are
already infected.  This applies not only to specific
cases such as transfusion and transplant surgery,
congenital transmission and accidents as described
above, but also to those infected in rural settings
prior to the implementation of large-scale vector
control interventions.  Even if all transmission were
immediately halted, there would remain some 16
million people requiring clinical attention over the
next 30 years or so.  In the context of the overall
Chagas disease control strategy, treatment of in-
fected individuals can be considered the second-
ary level of intervention, designed primarily to halt
the progression of disease.
Specific treatment - There are two drugs that
can be used for specific treatment of T. cruzi infec-
tion.  Nifurtimox manufactured by Bayer under the
trade name Lampit®  is given at 10-15 mg/kg body
weight per day, while benznidazole, manufactured
by Roche under the trade names Radanil®,
Rochagan® or Ragonil®,  is given at 5-7 mg/kg
body weight per day.  Treatment with either drug
is indicated in acute or recent infections, and in
congenital cases, with a good chance of radical
cure.  Acute infections are generally treated for up
to 60 days, but Brazilian experience indicates that
recent non-acute infections can be successfully
treated with a 10 day regime, provided that treat-
ment is started very soon after the initial infection.
Abbreviated treatment regimes have the advantage
of reduced likelihood of side effects, which gener-
ally commence after 8-10 days of treatment.  Side
effects are dosage dependent, and include malaise,
anorexia, loss of appetite and of concentration,
erythema, pruritus, and peripheral neuritis.  In some
cases, agranulocytosis and/or anaemia has been
observed, requiring interruption of treatment.  In
general, children tolerate treatment much better
than adults.
Use of nifurtimox or benznidazole has given
variable results in different countries, which may
reflect parasite strain differences.  In general how-
ever, complete cure can be expected with immedi-
ate treatment of accidental infections, and 30-70%
cure for treatment of acute infections.  Even if radi-
cal cure is not achieved, there is now strong evi-
dence that early treatment can prevent mortality
during the acute phase of infection, and can re-
duce the progression of disease in the subsequent
chronic phase - especially in relation to cardiac
lesions.  Viotti et al. (1997) present results of a 10
year follow-up of treated and non-treated individu-
als in the chronic phase of infection, showing sig-
nificantly improved clinical evolution in the treated
group, as well as reduced mortality. At the experi-
mental side, since the 70’s, important trials made
by Rowheder, Andrade (1999) and others have
shown that both drugs were effective at the tissue
level and that inflammatory response (and even
initial fibrosis) is reversible when the parasite is
killed throughout treatment.   Specific treatment
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of chronic infections should therefore be consid-
ered on a case-by-case basis, bearing in mind the
age of the patient since treatment is better toler-
ated in younger individuals, and the age of infec-
tion since greatest success is likely from more re-
cent infections (WHO 1991). The modern ten-
dency, nevertheless, is to give to the patient the
“benefit of the doubt” treating specifically the cases
of indeterminate and initial cardiac and digestive
chronic forms (Dias 1997).
Symptomatic treatment - Symptomatic or sup-
portive treatment for chronic phase patients has
advanced greatly in recent years.  Effective treat-
ment presupposes adequate access to medical at-
tention, with periodic clinical checks.  Patients with
indeterminate (asymptomatic) chronic infections
need a yearly check, whereas those with severe
arrhythmia or heart failure will require
hospitalisation and weekly or monthly clinical ex-
aminations.  In general, about 85% of chronic phase
patients can be followed through the primary health
care system, with periodic medical consultations,
serology and electrocardiograms (Dias 1990).
Management of the principal clinical manifesta-
tions can be summarised as follows:
Chronic cardiopathy: arrhythmias must be con-
trolled by adequate diagnosis and treatment - usu-
ally with amiodarone and other modern anti-
arrhytmic drugs such as propaphenone and
mexilethine.  Severe arrhythmias may require pace-
maker implant or other surgery. Cardiac surgery in
Chagas disease has being improved with the re-
section of aneurysms and of myocardium zones
where arrhytmogenic foci are detected.  Preven-
tion of heart failure is extremely important, and
requires detection before the onset of cardiac en-
largement.  In chronic Chagas disease, the final
phases of heart failure predict thrombi-embolic and
refractory situations based on severe weakness of
the cardiac muscles and advanced cardiac fibro-
sis.  In such cases, the only possible recourse may
be to heart transplantation.
Chronic digestive tract involvement: although
intestinal megasyndromes are well recognised in
many cases of advanced chronic infection, treat-
ment should be conservative in the early stages.
At the oesophagus  level, the Heller technique (ex-
tra-mucosa miotomy)  followed by plastic recon-
struction of the sphincter is considered the most
recommendable procedure for the cases up to 3rd
degree, not only correcting disphagia and other
current symptoms, but also preventing the evolu-
tion of  megaoesophagus in a large number of cases.
More aggressive surgical procedures are indicated
mainly for the most advanced cases with severe
dilatation and ectasy.  The worst manifestation of
megacolon, sygmoid volvulus, must be prevented
or immediately corrected, although it is regrettable
that the mortality rate from megacolon surgery re-
mains high, in spite of modern techniques.
Reintegration of chagasic patients into the com-
munity
This is the last stage in the classical sequence
of preventive medicine.  Often, a patient will panic
or become severely depressed when a positive di-
agnosis is revealed, even in the absence of clinical
manifestations.  The public image of Chagas dis-
ease is commonly associated with sudden death
and/or irreversible heart disease, an association that
has been progressively incorporated due to inap-
propriate and sensationalist reporting of a minor-
ity of severe cases.  Nevertheless, a person with
positive serology must be informed of this result
in order to avoid giving blood and to accept medi-
cal attention.  Clinicians and health workers must
give a realistic and non-sensationalist explanation
of Chagas disease, pointing out its natural history
and principal modes of transmission, as well as a
balanced view of the patient’s clinical prognosis.
Facing the chagasic individual, the role of the cli-
nician is to analyse carefully the case and discuss
objectively the particular situation with the patient
and family.  Most cases do not represent serious
clinical problems, and have little likelihood of se-
rious manifestations in the short and medium terms.
Moreover, available medical resources are continu-
ously improving in terms of disease management,
provided the patient is aware of the need for regu-
lar medical consultation and checks.  A rarely dis-
cussed problem is the psychological behaviour of
chagasic individuals, since most will suffer para-
sympathetic denervation, becoming hyper-reactive
to common ambient stimuli – they become perma-
nently stressed according  Vieira (in Dias 1990).
At the operational level, a present tendency is to
allocate psychological attention in those medical
services where chagasic people are attended (e.g.,
in Recife, São Paulo, Belo Horizonte, Goiânia and
Campinas (Brazil) and in Cordoba (Argentina).
At the community level also, correct and bal-
anced information must be given, especially to
emphasise that Chagas disease is not contagious,
and that the prognosis for infected individuals is
generally good.  This is particularly important in
terms of the basic rights of the chagasic individual,
the right to work (which is often refused to indi-
viduals merely because they present positive se-
rology), and the right to social security (which is
sometimes denied in cases of advanced heart dis-
ease).  These aspects require well-prepared clini-
cians and health workers, clear practical guidelines,
and an effective social security system.  In prac-
tice, the basic problem is to define the perspec-
113Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 94, Suppl. I, 1999
tives and conditions for chagasic individuals, tak-
ing into account their clinical state, their profes-
sion and general living conditions.  Each case must
be carefully evaluated, avoiding distress to the pa-
tient but equally avoiding false expectations.  At
present, millions of chagasic individuals from ru-
ral areas of Latin America are migrating into cit-
ies, seeking work and better social conditions.
Most remain in the chronic indeterminate phase of
infection, or in the initial stages of chronic heart or
digestive tract damage, and are physically quite
capable of carrying out the majority of professions.
On the other hand, some are in advanced stage of
chronic impairment, requiring medical attention
and a reduction in their physical labour in order to
reduce the risk of cardiac failure or sudden death.
But since many of the people infected with T .cruzi
are illiterate or poorly educated, it remains the re-
sponsibility of the social security system and the
medical profession to provide the best conditions
for their survival and development (Dias 1997).
SUMMARY OF THE PRINCIPAL EVENTS RELATED
TO  HUMAN CHAGAS DISEASE CONTROL FROM
1909 TO 1999
In order to have a general and chronologic com-
prehension of the facts appointed above, the fol-
lowing picture was prepared, showing the consid-
ered most relevant facts concerning to the control
of human Chagas disease, since its discovery and
according to the consensus of the majority of the
authors (Dias 1988, Coura 1997, Schofield & Dias
1999):
YEARS SUBJECT/OBSERVATION
1909 Carlos Chagas discovers the disease
1911 Chagas proposes vector control and
housing improvement and describes the
congenital transmission of Trypanono-
ma cruzi
1913 Brumpt describes xenodiagnosis;
Guerreiro and Machado develop comple-
ment fixation test
1916 Chagas emphasizes chronic heart disease
1918 Souza Araújo promotes a law con-
cerning house improvement in endemic
areas
1919-22 N Larrier and S Campos study congenit-
al transmission at experimental level
1926 Mazza begins the MEPRA project in
Jujuy, Argentina
1930-34 C Chagas and E Chagas employ EKG in
chronic Chagas heart disease
1932-36 Mazza claims for housing improvement
and tries some classical drugs in Chagas
disease
1935 IX MEPRA meeting; Romaña describes
his eye portal of entry sign
1935-44 Many acute cases are described in Ar-
gentina, Brazil, Uruguay and Venezuela.
Mazza warns about the risk of transfu-
sion and oral (mother milk) transmission
1943 Foundation of the Bambuí center in
Minas Gerais, Brazil, by Emmanuel
Dias, where trials are made of several
available insecticides (including cya-
nidegas), physical methods (flame-
thrower), housing improvement and
community participation
1944-46 Still in Bambuí, beginning of chronic car-
diopathy systematization; failure of DDT
against triatomines; Dias warns against
the risk of transfusion disease
1947-48 First laboratory trials against insects
(Busvine & Barnes 1947) and descrip-
tion of the action of HCH (gammexane)
against triatomines (Dias & Pellegrino,
Romaña & Abalos); first large scale sur-
vey employing serology and EKG in
non-selected population (Bambuí)
1949 First regional serological survey of blood
donors (Pellegrino, in Belo Horizonte,
Brazil); L Dao confirms in Venezuela the
congenital transmission of human
Chagas disease; Ramos and Freitas carry
on a serological and EKG inquiry in
Cássia dos Coqueiros, SP, Brazil
1950-52 In São Paulo, Brazil,  Nussensweig,
Freitas and Amato Neto confirm trans-
fusional transmitted Chagas disease. The
same group employs successfully  gen-
tian violet as chemoprophylactic agent
in blood banks. First large-scale trial with
gammexane against triatomines in
Uberaba, Minas Gerais, Brazil (E Dias,
Bustamante et al.)
1955 First experimental trial attempting Tri-
atoma infestans eradication in Bambuí
(E Dias)
1956 Publication of the definitive systemati-
zation of chronic heart Chagas disease
in Circulation by Laranja, Dias, Nóbrega
and Miranda
1957-58 Re-description of  Chagas disease diges-
tive forms by Köberle and others. Im-
portant serological and EKG survey in
the Córdoba region of Argentina, by
Rosenbaum and Cerisola. Important re-
gional epidemiological  surveys in Ven-
ezuela, by Pifano et al.
1959 Neghme and Schenone confirm in Chile
the results obtained in Bambuí against
T. infestans. E Dias emphasises the con-
cept of T. infestans eradication
1960-70 Beginning of vector control in São Paulo,
Brazil, and in Venezuela (National
Programme: using insecticide plus hous-
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ing improvement); regional actions in
Argentina and in various Brazilian states;
P Freitas introduces his concept of se-
lective spraying. Improvement of new se-
rological techniques for diagnosis (indi-
rect immunofluorescence, direct agglu-
tination and indirect haemagglutination);
registration of low levels of resistance
to organochlorine insecticides (dieldrin
and BHC) in part of Venezuela, promptly
resolved by changing the product to a
carbamate compound (propoxur);  first
optimistic results of nifurtimox, against
acute forms of human Chagas disease;
improvement of chemoprophylaxis in
blood banks of Argentina and Brazil,
besides the increasing of prevalence sur-
veys among blood donors in the entire
Continent; still timid improvement of
blood bank serological control is ob-
served  in endemic regions; the first posi-
tive serological results are registered in
worked areas of Brazil (Bambuí, São
Paulo), Venezuela (Belén, Eneal) and Ar-
gentina; beginning of the trials with new
anti-arrhythmic drugs (amiodarone) for
chronic cardiopathy
1970-80 Beginning of the national programme in
Uruguay (1972); reformulation of the
Brazilian programme in 1975, based on
E Dias’ ideas concerning a systemic ap-
proach taking into account the continu-
ity of the actions in contiguous areas;
complete revision of transfusion trans-
mitted Chagas disease by Cerisola et al.
(Argentina); first community based sur-
veillance against triatomines in Bambuí;
beginning of the national entomological
and serological surveys in Brazil; im-
provement of applied and basic research
in Brazil supported by the Ministry of
Health and Brazilian Research Council
[Integrated Programme of Endemic Dis-
eases (PIDE, followed some years later
by TDR/UNDP-WB-WHO)]; first trials
with benznidazole; Alma-Ata meeting,
bringing the  concept of Public Health
activities based on the primary health
care system; generalisation of the con-
cept of  the regional differences on
Chagas disease morbidity; still a very
slow advance in the coverage of blood
banks with preventive serology and/or
chemoprophylaxis; beginning of the an-
nual meeting on basic research
(Caxambu, Brazil); at the end of the de-
cade, a book edited by Zigman Brener
and Zilton Andrade as well as an  Inter-
national Congress on Chagas Disease
(Rio de Janeiro), call the attention of
authorities and scientific community to
the disease and its control; in New York,
publication of Lent and Wygodzinsky’s
compendium about triatomines; in Ven-
ezuela, Gomez-Nuñes develops a simple
model of passive sensor to triatomines;
spreading of the HAI and IIFT serologi-
cal tests in endemic countries, slowly re-
placing the pioneer CFT; first trials of
pyrethroid insecticides in Minas Gerais
and Rio de Janeiro (Brazil) and in Ar-
gentina
1980-90 Aids emergence and dispersion, induc-
ing the reformulation of haemotherapy
throughout the world, so making com-
pulsory the serological screening of
blood donors; progressive replacement
of ancient insecticides by modern pyre-
throids; mathematical simmulations (J
Rabinovich) show that vector control is
feasible mainly when insecticide, hous-
ing improvement and social progress are
associated;  first regional programmes in
Chile and Bolivia; political decision in
Brazil, resulting in the allocation of re-
sources to expand programme coverage
to entire endemic area, without disconti-
nuity; beginning of the annual meeting
on applied research in Brazil (Araxá,
then Uberaba) and some important peri-
odical meetings in Argentina (Carlos
Paz, La Falda, etc.); beginning of the
“Programa de Salud Humana”, headed
by Dr Pilar Alderette in Argentina
(BIRD/Universidad El Salvador), stimu-
lating several emergent regional groups
for the diagnosis and control of Chagas
disease in Argentina, Uruguay, Chile,
Brazil, Paraguay and Bolivia; the results
obtained by the control programmes in
São Paulo and other Brazilian parts  call
attention to vigilance strategies formerly
developed  in Bambuí;  detailed studies
of the population dynamics of
Triatominae developed in Venezuela
(Rabinovich), Brazil (Marsden,
Schofield) and Argentina (Gorla) help to
improve new control strategies; impor-
tant publications in Brazil about the ecol-
ogy of vectors and reservoirs (O Forattini
& M Barretto); a national electrocardio-
graphic survey is carried out in Brazil,
showing regional differences; financial
constraints result in the decreasing of
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Venezuelan  programme; development of
the ELISA technique for serology; gen-
eral improvement in the medical atten-
tion for acute and chronic patients,
mainly at the level of cardiac arrythmias,
cardiac failure and mega-syndrome di-
agnosis and surgery; important advances
in cardiopathy studies with the
generalisation of ecocardiographic,
holter, exercise tests and other investi-
gation procedures; generalisation of car-
diac transplantation and pace-maker im-
plantation; spreading of social and cost-
benefit studies about the disease and its
control; introduction of Aedes aegypti
and dengue fever in Brazil, resulting in
relative disactivation of Chagas disease
programme;   the entomological results
in Brazil Uruguay and Argentina make
clear that elimination of T. infestans is
an attainable goal, and that the surveil-
lance strategy,  peridomestic Triatominae
and secondary species will constitute a
challenge for the next decade; in some
countries (Argentina, Brazil, Uruguay),
a law about blood transfusion is imple-
mented
1990-99  Preliminary studies at the scientific level
and final resolution of the Ministries of
Health of Argentina, Bolivia, Brazil,
Chile, Paraguay and Uruguay implement
the “Southern Cone Initiative for elimi-
nation of  T. infestans and Control of
Transfusion Transmitted Chagas Dis-
ease” (Brasília); progressive disacti-
vation of PIDE and Chagas disease TDR
research programmes; ECLAT research
network launched with support from EC
and Switzerland; improvements are made
in chemoprophilaxys of stored blood
banks in order to short the time of para-
site disactivation (Moraes Souza); pro-
gressive disactivation of the conventional
vertical programmes in Argentina, Brazil
and Venezuela, because of the transition
to horizontal peripheral systems and the
new model of  “modern and small central
structures”; improvement of the research
to new areas, such as Amazon Region and
to other less well studied regions (Cen-
tral America, México); Paraguay begins
national programme in 1994; longitudi-
nal, sectional and experimental studies
show that treatment with benznidazole
and/or nifurtimox can be effective in
young and even adult patients, providing
parasitological cure and even the interrup-
tion of the progression of chronic lesions;
other endemic countries implement blood
bank control; results of  vector control in
Brazil and Uruguay show  a positive  im-
pact on decreasing of transfusion and con-
genital transmitted Chagas infection, as
well as on the morbidity and mortality
patterns of the disease; new regional “ini-
tiatives” arise in Central America and
Andean Regions; Mexico starts a regional
pilot programme against domiciliated
triatomines;  the Global Conference on
Disease Elimination (Atlanta, USA), con-
siders Chagas disease as a clear candidate
for elimination up to the year 2010; in
1999, Bolivia assumes an historical deci-
sion to implement a complete national
control programme in all endemic areas,
allocating external and national resources
to guarantee its continuity over the next
five years; at the same time, national con-
trol programmes start in Peru, Colombia
and Central America (Honduras, El Sal-
vador, Nicaragua and Guatemala, and a
plan is made for Costa Rica); entomologi-
cal studies carried out through the ECLAT
net work show the possibility of Rhodnius
prolixus elimination in Central America,
since this species is out of its original dis-
persion centre
This very short and simple summary reveals to
us a history involving men, research, social poli-
cies, political will and  technological development.
It must be emphasised that HCD never received a
high social priority because of several and differ-
ent factors such as the very weak socially involved
population (poor, rural, isolated, non-organised,
etc.) and the lacking of specific treatment for sev-
eral years,  of medical interest on the disease, of
formal education involvement, of an  effective
policy considering agriculture and rural housing
in endemic countries, and also the very weak mar-
ket concerning the main trade tools involved in
HCD: insecticides and laboratory reagents for di-
agnosis. It is very peculiar the fact of scientific
community involvement in all this history, since
Carlos Chagas, following his examples with a very
clear  social compromise, many times leaving the
hospitals and laboratories to push on political de-
cisions. In the history of Chagas disease control,
was necessary more than research and epidemio-
logical data to move on national and regional
programmes. An additional  work was required to
sensitise the public opinion, to influence the na-
tional governments and to stimulate leadership for-
mation and decision making (Morel 1998).
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THE PRESENT SITUATION OF CHAGAS DISEASE
CONTROL IN ENDEMIC COUNTRIES
In a general way, the endemic countries can be
considered according their epidemiological situa-
tion (vectors, transmission rate, prevalence and
morbidity) and by the state of national control
programmes.  Serology of children and blood do-
nors provides useful epidemiological information,
as do electrocardiographical surveys of infected
and non-infected individuals (Schmunis 1991, Dias
& Coura 1997). Unfortunately, representative and
comparable data are not available in the majority
of countries, chiefly those concerning morbidity.
Chagas disease is not homogenously distributed
in the endemic countries, but tends to be in micro-
regional clusters that generally depend of the level
of domestic colonisation by vector species.   Na-
tional and regional control programmes prioritise
chemical control of vectors, together with screen-
ing of blood donors as the basic strategy to HAT
control, supported by Health Education and com-
munity organisation. Chemoprophylaxis of trans-
fused blood has not been implemented in recent
years (WHO 1991, Dias 1997). In the Southern
Cone, chronic heart disease is the bigger problem
among infected people of the region, being present
in more than 20% of them, while digestive “megas”
affect up to 10%. Acute cases usually disappear
immediately when a locality is treated.  At present,
Argentina, Bolivia, Brazil, Chile, Paraguay and
Uruguay are implementing programmes for the
elimination of T. infestans, as the best way to reach
the minimum level of disease transmission. Nev-
ertheless, secondary triatomines such as T. sordida,
T. pseudomaculata and P. megistus can invade
dwellings (chiefly in Brazil) and must be faced
throughout effective and continuous vigilance. The
most advanced programmes are in Uruguay, Chile,
Brazil and Argentina, where current levels of trans-
mission are now low (see Tables III, V). In these
countries, the control of blood banks is also being
improved, with a high degree of coverage and very
low prevalence of infected blood donors. Finan-
cial support of national programmes in these coun-
tries has been  maintained in the last eight years,
but the availability of trained personnel is declin-
ing, either because of the decentralisation policies
or by the demand of other emergent problems,
chiefly dengue fever. Progressive disactivation of
traditional programme structures is leaving admin-
istrative gaps at  regional and municipal levels,
which generally are not prepared to assume the
control activities and to maintain the consequent
surveillance.  In Bolivia, original centre of disper-
sion of T. infestans, the epidemiological indicators
are high, with a mean rate of infection in blood
donors of around 40% in endemic areas,  and over
5% in non endemic regions, while the only con-
trolled blood bank is in Sta. Cruz City. Bolivia has
launched a new national programme, with Presi-
dential backing, and – for the first time – adequate
financial resources (more than US$ 30 million) to
spray approximately 700,000 houses and to con-
trol all blood banks within the next five years.
Paraguay has also an important level of transmis-
sion: in the Chaco Region the mean house infesta-
tion rate by T. infestans reaches more than 30%,
while the prevalence of infection is over 25%
amongst pregnant women. The vector control
programme still remains in a phase of organisation.
Nevertheless, the control of blood banks and a na-
tional policy to detect and to treat congenital cases
are rapidly being improved in the country. Peru
has an  important endemic area (Arequipa and
Tacna regions), and is now developing a national
programme for the elimination of T. infestans from
the infested southern departments, and progressive
control of blood banks.  As a whole, the elimina-
tion of T. infestans  is now considered an attain-
able goal, since this insect has no wild foci (except
in limited areas of central Bolivia) and infestation
rates decrease dramatically in all sprayed areas.
In the Andean Pact region (Ecuador, Colom-
bia and Venezuela)  the main vectors are R.
prolixus, and T. dimidiata, with several other spe-
cies of local importance. R. prolixus is the princi-
pal regional vector in Venezuela and Colombia,
where it is highly domesticated. The principal dis-
ease impact is due to chronic cardiopathy, which
affects about 20% of infected Venezuelan individu-
als, whereas, digestive chronic forms seem to be
not observed in this region. Venezuela has imple-
mented a large-scale programme of Chagas dis-
ease control, where during more than 20 years there
was intensive house spraying and more than
600,000 rural houses were  improved in endemic
areas. Unfortunately, the national programme has
weakened in the last decade, with progressive loss
of  human and financial resources, the complexi-
ties of decentralisation and the emergence of den-
gue.  In 1997 however, following encouraging re-
sults in the Southern Cone, a new Andean Pact
initiative was agreed.  Colombia has quickly de-
veloped improved systems of blood bank control,
and is now implementing a national programme to
eliminate R. prolixus;  Ecuador has begun vector
control trials (especially in Guayaquil), and inten-
sified vector control activities in Venezuela are
expected.
The Central American initiative, also launched
at the end of 1997, mainly involves Guatemala,
Honduras, El Salvador and Nicaragua.  In these
countries, the most important vector is R. prolixus,
which is considered a feasible candidate for eradi-
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cation from the region since it appears to be exclu-
sively domestic.  Moreover, genetic studies show
that it was probably imported some 80 years ago
from Venezuela, and now has an extremely lim-
ited genetic repertoire compared to the original
Venezuelan and Colombian forms.  R. prolixus is
associated with very high rates of human infection
(typically over 40% in Honduras and Guatemala)
but it has a limited and focal distribution.  In con-
trast, T. dimidiata is extremely widespread in Cen-
tral America – even in periurban areas – but is gen-
erally associated with human infection rates of 8-
12%.  T. dimidiata cannot be considered a candi-
date for eradication since it also has widespread
sylvatic foci, so that its control will require the
development of continuous community-based vigi-
lance systems.  The distribution of T. dimidiata
extends from southern Mexico throughout Central
America into Panama, Colombia, Ecuador and
northern Peru.  In Panama, the main vector of hu-
man Chagas disease  is R. pallescens, with very
low house colonisation. Although results from re-
cent surveys have yet to be fully analysed, it seems
that the highest prevalence rates are found in Gua-
temala, Honduras and Nicaragua, with a mean rate
of infected blood donors between 4 and 8%.
Chronic Chagas heart disease seems less common
and less severe compared to Southern Cone coun-
tries, and digestive forms are rare. But the morbid-
ity and prevalence of HAT in Central American
countries are more intense in those areas infested
by R. prolixus, rather than those where T. dimidiata
(or other species) dominate.
In Mexico, in spite of an excellent tradition of
Chagas disease research in the 1950s and 1960s, the
importance of Chagas disease was largely overlooked
until the current decade.  In 1992, a large scale sero-
logical survey of blood donors and rural populations
indicated an overall infection prevalence of over
500,000 cases, and subsequent surveys have con-
firmed high levels of infection, especially in the
southern and central states.  Since 1997, an improved
system of screening of blood donors has been pro-
gressively developed, although coverage remains
incomplete.  Vector control activities have yet to be
implemented on a large scale, although the first tri-
als using modern pyrethroids were begun in 1998.
The main vectors are members of the T. protracta
group of species (especially T. barberi) and mem-
bers of the T. phyllosoma group (especially T.
pallidipennis).  All of these seem to have extensive
sylvatic ecotopes as well as colonising peridomestic
and domestic habitats, and are subject of major re-
search efforts to clarify the most appropriate meth-
ods for control and surveillance.
Data on the remaining countries remains scarce.
Amongst the caribbean islands, several report the
presence of potential vectors – particularly T.
maculata and P. geniculatus in islands close to the
mainland, and members of the T. flavida group in
Cuba and Jamaica – but there appears to be no ac-
tive transmission of human Chagas disease on these
islands.  In the Guianas (Guyana, Suriname and
French Guiana) several species of Rhodnius and
Panstrongylus have been reported, occasionally
entering houses, and a few acute cases of Chagas
disease have been reported from parts of French
Guiana.  At present however, there are no national
programmes for surveillance or control of the dis-
ease in these countries, either in terms of vector
control or in monitoring of blood donors.
RESEARCH NEEDS AND FINAL CONSIDERATIONS
The most visible framework shows that re-
search is still necessary either to solve some actual
constraints or to prevent possible epidemiological
changes in the future. First of all, the basic control
strategies are available and can provide a good
chance that HAT transmission can be substantially
reduced within the next few years, in spite of some
constraints existing at each control level. At the
other side, about 16 million of yet infected indi-
viduals deserve medical attention, an important
subject in which the researcher finds higher chal-
lenges than in primary control. To the next future a
very low level of transmission is expected, a fact
that claims for a better and long term sustained
epidemiological surveillance. Secondary vector
species and an  effective management of peri-do-
mestic ambient require more and more attention.
Considering the different control levels, the more
urgent research needs could be summarised as fol-
lows (Table IV).
Many accounts of Chagas disease present a dis-
mal picture of incurable infection consigning mil-
lions to chronic debility, ignored by all but a hand-
ful of research workers and rural clinicians.  But
this picture has changed dramatically in recent
years.  Advances in diagnosis, and improvements
in understanding and treating the infection, have
led to much better disease management and in-
creased awareness that chagasic individuals can
generally fulfil an entirely normal role in society.
Most importantly perhaps, there is now wide rec-
ognition that transmission of the parasite can be
halted, with national, regional and international
programmes designed to improve the screening of
blood donors and implement effective control of
the insect vectors.  Today, over vast areas of the
once endemic regions, acute cases of Chagas dis-
ease are no longer seen, and the risk of new infec-
tion (of all transmission routes) is diminishing rap-
idly as the control programmes achieve wider geo-
graphical coverage.  And vector control has brought
additional advantages to rural communities,
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whereby families can now sleep undisturbed, in
even the poorest of dwellings, without the risk of
attack by blood-sucking Triatominae. The dilemma
remains in the same social and biological factors
involved in HAT and very early detected by Carlos
Chagas: poverty, and low political priority of af-
fected populations, by one side, and a terrible
chronic disease transmitted by the  opportunistic
insect, at the other.
In addition to the social and medical benefits of
Chagas disease control, the financial benefits are also
substantial.  In planning the Southern Cone
programme, it was estimated that an investment in
Chagas disease control would produce an annual eco-
nomic return equivalent to 14% in medical savings
alone (Schofield & Dias 1991).  Since then, studies
in Brazil have shown a real economic rate of return
of over 30% (Akhavan 1997) while studies in Ar-
gentina indicate rates of return in excess of 60% (Del
Rey et al. 1995, Basombrio et al. 1998). For Brazil
during the period 1983-1996, the analysis indicates a
national expenditure on Chagas disease control of
about $400 million, producing savings of over $900
million in terms of improved survivorship alone, pre-
venting at least 277,000 new cases of infection and
85,000 deaths (Akhavan 1997).
The main challenge is to consolidate and extend
these successes to implement control programmes
TABLE IV
Research needs to Chagas disease control at present time, according to the different epidemiological levels
Control level Required research General comments
Vector control Better insecticide and methodology at the Community participation and the
peri-domestic level maintenance of political will in
Better triatomine trapping in low densities very low bug densities will be a
Better organisation of epidemiological major challenge in the next future
surveillance
Monitoring of sylvatic-domestic
triatomine migration
Monitoring of triatomine resistance to
insecticides
Transfusion transmission More rapid, sensible and specific serology Cost-benefit relations worse in
More rapid, effective and non toxic drug in advanced phases of the programme,
chemoprophilaxis Institutional research when the level of transmission is
about the quality of haemotherapy very low. In general, better indica-
tion and quality of hemotherapy are
required, mainly in smaller towns
Congenital Transmission Development of tools to detect precociously Better organisation and coverage
congenital transmission Immunoprophilaxis on peripheral primary health care
(still not available) system  are required
Accident and organ More efficient drugs to chemoprophilaxis There is not adequate registration/
transplantation Studies on risk factors information
Specific treatment More effective and less toxic drugs Indications for treatment  are
increasing to chronic cases
Symptomatic treatment Cardiopathy: more efficient drugs and Precocious diagnosis and adequate
procedures to control arrythmias, heart medical and social attention
failure and trombo-embolic syndrome; remain the main challenge for
improvement of precocious diagnosis of human Chagas disease management
cardiopathy and immune modulation of
fibrosis (not available); digestive: impro-
vement of farmacologic and surgical treat-
ment of digestive lesions
Programme organisation How to improve the minimum continuity Improvement of regional reference
and quality, as well as the information flow centres concerning control,
in horizontal and decentralised operative epidemiology, medical care,
structures? Analysis of causes, conse- diagnosis, entomology, etc., is
quences and risk factors involving the required
failure and weakening of national and
regional programmes
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in countries where Chagas disease exists but is not
fully confronted, and to maintain those programmes
that have already been launched.  In the first case,
political priority must be assumed and reinforced
by consistent epidemiological data.  For existing
programmes, as in Brazil, the priority is to maintain
the political momentum in order to extend
programme coverage.  And this is by no means a
simple task within the extensive policies of
decentralisation, which are now being implemented
in Brazil and elsewhere. The basic problems, here,
concern with two different situations: (a) how to
maintain efficiency and effectiveness at peripheral
levels which many times are not ready to assume
this kind of work, and, (b) how to assure epidemio-
logical and social priorities, at those levels, where
personal and political interests use to be the main
determinants of actions. We have reached the stage
where effective disease control is less of a technical
problem, but rests more and more in the domain of
administration and organisation.
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